Silence Therapeutics (NASDAQ: SLN) announced it will host a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV). The results are scheduled to be presented on Monday, August 10, 2026, at 8:00 a.m. EDT. Sector: Biotechnology / RNA Therapeutics Key Highlights 🧬 Phase 2 SANRECO topline results for divesiran 🩸 Trial targets polycythemia vera (PV) 📅 Results discussion scheduled for August 10, 2026 ⏰ Conference call at 8:00 a.m. EDT 🚀 Results could provide an important clinical milestone for Silence Therapeutics Why It Matters The SANRECO results could provide key evidence on divesiran's potential in polycythemia vera and represent an important catalyst for Silence Therapeutics' clinical pipeline. Read More: https://www.thinksabio.com/reports/isr/SLN